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Abstract
Background: Cyclin D1 is an important regulator of G1-S phase cell cycle transition and has been shown
to be important for breast cancer development. GSK3β phosphorylates cyclin D1 on Thr-286, resulting in
enhanced ubiquitylation, nuclear export and degradation of the cyclin in the cytoplasm. Recent findings
suggest that the development of small-molecule cyclin D1 ablative agents is of clinical relevance. We have
previously shown that the histone deacetylase inhibitor trichostatin A (TSA) induces the rapid ubiquitin-
dependent degradation of cyclin D1 in MCF-7 breast cancer cells prior to repression of cyclin D1 gene
(CCND1) transcription. TSA treatment also resulted in accumulation of polyubiquitylated GFP-cyclin D1
species and reduced levels of the recombinant protein within the nucleus.
Results: Here we provide further evidence for TSA-induced ubiquitin-dependent degradation of cyclin
D1 and demonstrate that GSK3β-mediated nuclear export facilitates this activity. Our observations
suggest that TSA treatment results in enhanced cyclin D1 degradation via the GSK3β/CRM1-dependent
nuclear export/26S proteasomal degradation pathway in MCF-7 cells.
Conclusion: We have demonstrated that rapid TSA-induced cyclin D1 degradation in MCF-7 cells
requires GSK3β-mediated Thr-286 phosphorylation and the ubiquitin-dependent 26S proteasome
pathway. Drug induced cyclin D1 repression contributes to the inhibition of breast cancer cell proliferation
and can sensitize cells to CDK and Akt inhibitors. In addition, anti-cyclin D1 therapy may be highly specific
for treating human breast cancer. The development of potent and effective cyclin D1 ablative agents is
therefore of clinical relevance. Our findings suggest that HDAC inhibitors may have therapeutic potential
as small-molecule cyclin D1 ablative agents.
Background
Cyclin D1 is an important regulator of G1-S phase cell
cycle transition. Active cyclin D1-cyclin dependent kinase
4/6 complexes phosphorylate retinoblastoma protein,
resulting in release of sequestered E2F transcription fac-
tors and subsequent expression of genes required for pro-
gression into S phase [1]. Cyclin D1 accumulation is
required for progression through the G1 phase of the cell
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cycle. Interestingly, cyclin D1 degradation at the end of G1
phase is also necessary for progression into S phase and
failure to degrade cyclin D1 results in G1 arrest [2]. Fol-
lowing S phase, cyclin D1 levels again rise steadily if
mitogenic stimuli remain present and elevated levels of
cyclin D1 are required for continued cell cycling [3]. Reg-
ulating the rate of ubiquitin-dependent degradation ena-
bles cells to rapidly adjust the level of cyclin D1 protein
despite a constant rate of continued synthesis.
Following its discovery, cyclin D1 was localized to the
nucleus and its rapid ubiquitin-dependent degradation
shown to require phosphorylation at Thr286 by glycogen
synthase kinase 3β (GSK3β) [4]. Additional studies led to
the proposal of a model in which at the end of the G1
phase, GSK3β migrates into the nucleus where it phos-
phorylates cyclin D1 [5], resulting in ubiquitylation,
nuclear export and degradation of the cyclin in the cyto-
plasm [4]. Cyclin D1 nuclear export is dependent on the
CRM1 complex and requires prior phosphorylation of
cyclin D1 by GSK3β. Inhibition of CRM1 with leptomycin
B, GSK3β inhibition, or T286A mutation inhibits ubiqui-
tin-dependent cyclin D1 degradation [4-6]. Early experi-
ments suggested that GSK3β-dependent phosphorylation
is required for cyclin D1 ubiquitylation [7] but cyclin D1
can also be ubiquitylated independently of GSK3β via
unknown mechanisms [8].
Recent studies suggest that cyclin D1 regulation at the pro-
tein level may be more complex than previously thought.
Firstly, a constitutively nuclear splice variant (cyclin D1b)
that lacks the C-terminal domain including Thr286 was
neither more stable than the wild type cyclin nor accumu-
lated to excessive levels [9]. These observations are sur-
prising for the reasons stated above. Secondly, Guo et al.
[3] demonstrated that cyclin D1 is degraded throughout
the cell cycle although its destruction is enhanced during
S phase. The observation that a Green Fluorescent Protein
(GFP)-tagged cyclin D1 T286A mutant was more stable
during S phase, linked phosphorylation at this residue to
rapid protein degradation. Thr286 phosphorylation
therefore enhances cyclin D1 degradation during S phase.
However, GSK3β activity was unchanged throughout the
cell cycle and the mutant cyclin D1 protein did not accu-
mulate [3]. The observed failure of cyclin D1b or Thr286
mutants to accumulate to excessive levels suggests the
existence of an alternative pathway for cyclin D1 destruc-
tion that is independent of Thr286 phosphorylation and
nuclear export. In addition, the rapid degradation of cyc-
lin D1 by the 26S proteasome following DNA damage
does not require either GSK3β activity or Thr286 phos-
phorylation [10]. Furthermore, Thr286-independent
ubiquitylation has been previously described, suggesting
that rapid cyclin D1 degradation can occur by other path-
ways in the absence of GSK3β activity. More recently, the
serine/ threonine kinase Mirk/ Dyrk1B was shown to
enhance cyclin D1 degradation by phosphorylating
Thr288. Mirk activity is restricted to the G0-/early G1-
phase of the cell cycle and may not regulate cyclin D1 in
actively cycling cells [11].
The Skp2 F-box protein is a specificity conferring subunit
of the Skp1-Cullin-F-box (SCF) complex that has been
associated with cyclin D1 ubiquitylation [12]. Skp2
'knockdown' by siRNA abolishes degradation and results
in accumulation of cyclin D1 [13]. High levels of Skp2 can
be detected at S phase, around the time that cyclin D1
phosphorylation and degradation are enhanced [14].
Although much attention has been focused on Thr286
phosphorylation, the decline in cyclin D1 levels during S
phase may also reflect increased ubiquitylation and degra-
dation. We have previously shown that the histone
deacetylase (HDAC) inhibitor trichostatin A (TSA)
induces the rapid ubiquitin-dependent degradation of
cyclin D1 in MCF-7 breast cancer cells prior to repression
of cyclin D1 gene (CCND1) transcription [15] TSA-
induced cyclin D1 degradation is associated with Skp2
upregulation and Skp2 siRNA inhibits this response. In
MCF-7 cells transiently expressing GFP-cyclin D1, TSA
treatment resulted in accumulation of polyubiquitylated
GFP-cyclin D1 species and reduced levels of the recom-
binant protein within the nucleus. TSA therefore induces
the rapid loss of cyclin D1 in MCF-7 cells by enhancing its
ubiquitin-dependent degradation.
Cyclin D1 ablation has been shown to provide specific
protection against breast cancer and can overcome drug
resistance by sensitizing these cells to apoptotic signals
[16,17]. Anti-cyclin D1 therapy may be thus be important
for treating human breast cancer [18,19]. Several HDAC
inhibitors with structural similarity to TSA are currently in
development or early phase clinical investigation [20-23].
We thus wished to investigate further, the mechanisms
underlying the effect of TSA on cyclin D1 degradation in
MCF-7 breast cancer cells. Cyclin D1 levels are elevated in
this cell line as a result of its defective ubiquitin-depend-
ent degradation [12]. Here we provide further evidence for
TSA-induced ubiquitin-dependent degradation of cyclin
D1 and demonstrate that GSK3β-mediated nuclear export
facilitates this activity. The development of HDAC inhibi-
tors as small-molecule cyclin D1 ablative agents may thus
be of clinical relevance.
Results
TSA induces cyclin D1 26S proteasomal degradation
In previous studies we demonstrated that TSA induces the
rapid degradation of cyclin D1in MCF-7 cells. Co-culture
of TSA-treated cells with the proteasomal inhibitor
MG132 inhibited cyclin D1 degradation, demonstrating a
role for the ubiquitin-dependent degradation pathwayMolecular Cancer 2006, 5:8 http://www.molecular-cancer.com/content/5/1/8
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Effect of TSA on GFP-Cyclin D1 localization in MCF-7 cells Figure 1
Effect of TSA on GFP-Cyclin D1 localization in MCF-7 cells. Cells were transfected with expression vectors encoding wild type 
GFP-Cyclin D1 (GFP-Cyclin D1WT). 24 h after transfection, cells were treated with TSA (1 µM) alone or in the presence of 
MG132 (50 µM) or leptomycin B (LMB) (10 ng /ml) for 6 h. Cells were fixed in ice cold methanol for 5 min, counterstained 
with DAPI and examined by fluorescence microscopy. Cells with predominantly cytoplasmic GFP-cyclin D1 are indicated by 
grey arrows.Molecular Cancer 2006, 5:8 http://www.molecular-cancer.com/content/5/1/8
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Thr286 phosphorylation mediates the effect of TSA on GFP-cyclin D1 cytoplasmic accumulation A, Thr-286 but not Thr-288 is  required for TSA induced cyclin D1 nuclear exclusion Figure 2
Thr286 phosphorylation mediates the effect of TSA on GFP-cyclin D1 cytoplasmic accumulation A, Thr-286 but not Thr-288 is 
required for TSA induced cyclin D1 nuclear exclusion. MCF-7 cells were transfected with vectors encoding GFP-Cyclin D1WT, 
GFP-Cyclin D1T286A, GFP-Cyclin D1T288A or GFP-Cyclin D1T286,-288A for 24 h and treated as for Figure 1. GFP-Cyclin D1 locali-
zation was scored by quantitative fluorescence microscopy counting >200 cells in three separate experiments. B, Effect of 
MG132 on wild type and mutant GFP-Cyclin D1 protein levels. Cells were transfected as in A and then treated with MG132 
(50 µM) for 6 h. Cell lysates were separated by 4–20 % SDS-PAGE and immunoblot analysis was done using antibodies against 
GFP and actin.
B
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[15]. In MCF-7 cells transiently expressing GFP-cyclin D1,
the recombinant protein localizes to both the cytoplasm
and nucleus of most cells (Figure 1, top panel). Co-culture
with TSA and MG132 however, promoted the localization
of GFP-cyclin D1 within the cytoplasm of most cells. (Fig-
ure 1, gray arrows). In contrast, co-culture of MCF-7 cells
with TSA and leptomycin B (LMB), an inhibitor of CRM1-
dependent nuclear export, promoted the nuclear accumu-
lation of GFP-cyclin D1 (Figure 1, bottom panel). We
wished to determine the role of GSK3β in mediating this
effect of TSA on cyclin D1 localization. Site-directed muta-
genesis was used to mutate wild type GFP-cyclin D1 resi-
dues Thr286 and/or Thr288 to alanine. MCF-7 cells
transiently expressing wild type or mutant GFP-cyclin D1
were co-cultured with TSA and MG132 for 6 h and subse-
quently examined by quantitative fluorescence micros-
copy. Although the expression of the recombinant protein
was very high in some cells, a distinct cytoplasmic, nuclear
or nucleo-cytoplasmic localization could be observed in
most transfected cells (Figure 1). GFP-cyclin D1 localiza-
tion did not appear to be dependent on the level of recom-
binant protein expression (Figure 1). Cells with a >80 %
cytoplasmic or nuclear localization of the recombinant
protein were scored as cytoplasmic and nuclear respec-
tively. All other cells were scored as nucleo-cytoplasmic.
More than 200 cells from at least eight separate fields were
scored from three separate experiments for quantitation.
Wild type and mutant GFP-cyclin D1 localization was pre-
dominantly nucleo-cytoplasmic in the majority of cells
examined (Figure 1 (gray arrows), Figure 2A). Treatment
with either TSA or MG132 alone did not affect GFP-cyclin
D1 localization. Co-culture with TSA and MG132 how-
ever, resulted in a significant increase in the number of
cells in which GFP-cyclin D1 localization was predomi-
nantly cytoplasmic. Mutation of Thr286 alone or together
with Thr288 abolished the effect of TSA on GFP-cyclin D1
localization. No effect on localization was observed when
cells expressing GFP-cyclin D1T288A were co-cultured with
TSA and MG132. While these experiments did not allow
us to distinguish clearly between increased nuclear degra-
dation, nuclear export and cytoplasmic sequestration,
they none the less suggested a possible role for GSK3β-
dependent Thr286 phosphorylation in mediating the
effect of TSA on GFP-cyclin D1 localization. We previ-
ously reported, that TSA enhances the accumulation of
polyubiquitylated GFP-cyclin D1 when 26S proteasomal
degradation is inhibited by MG132 [15]. It is possible that
TSA treatment results in the cytoplasmic accumulation of
polyubiquitylated cyclin D1 when 26S proteasomal deg-
radation is inhibited.
GSK3β-dependent nuclear export facilitates the Rapid 
TSA-induced degradation of Cyclin D1
Our previous observation that residue Thr286 was
required for the apparent TSA-induced effect on GFP-cyc-
lin D1 localization (Figure 1 and Figure 2A), suggested a
role for GSK3β in facilitating TSA-induced cyclin D1 deg-
radation in MCF-7 cells. We therefore investigated the
effect of inhibiting GSK3β activity or CRM1-dependent
nuclear export on the cyclin D1 degradation response to
TSA. Endogenous levels of GSK3β were reduced by siRNA
to >70% of the level in mock transfected MCF-7 cells (Fig-
ure 3A). GSK3α levels were unchanged confirming the
specificity of the siRNA oligonucleotide pool. The cellular
levels of cyclin D1 mRNA and protein in GSK3β knock-
down cells were comparable to those in mock transfected
cells. TSA-induced cyclin D1 degradation was partially
inhibited in GSK3β knockdown cells. In contrast, MG132
completely abolished the cyclin D1 degradation response
to TSA. Total GSK3α and GSK3β levels were unaffected by
TSA, even after 24 h of treatment (Figure 3B). Specific
inhibition of GSK3 activity with SB216763 also resulted
in only a partial abrogation of TSA-induced cyclin D1 deg-
radation. SB216763 activity was monitored by immunob-
lot analysis of the cellular levels of β-catenin, an
endogenous GSK3β substrate protein. Although pretreat-
ment of MCF-7 cells with up to 20 µM SB216763 for 24 h
failed to completely abolish TSA-induced cyclin D1 degra-
dation, β-catenin stabilization was observed at concentra-
tions as low as 5 µM (Figure 3C). The inability of
SB216763 to abrogate TSA-induced cyclin D1 depletion
did not therefore result from a loss of activity or inappro-
priately low concentration of inhibitor. These observa-
tions suggested that while GSK3β activity could enhance
TSA-induced cyclin D1 degradation in MCF-7 cells, this
activity was not indispensable for cyclin D1 ubiquitin-
dependent degradation. TSA induces cyclin D1 degrada-
tion in MCF-7 cells prior to repressing its transcription
and without inhibiting protein synthesis [15] The stabili-
zation of β-catenin and partial inhibition of TSA-induced
cyclin D1 degradation by SB216763 may be due to the
existence of basal GSK3β activity in the asynchronously
growing MCF-7 cells used in this study.
We also investigated further, the effect of inhibiting
CRM1-dependent nuclear export on TSA-induced cyclin
D1 degradation. Treatment of MCF-7 cells with 5–10 ng /
ml of leptomycin B alone for 6 h, did not lead to a signif-
icant increase in total cyclin D1 levels above those of vehi-
cle control treated cells (Figure 3E). Nonetheless,
pretreatment of MCF-7 cells with leptomycin B partially
inhibited TSA-induced cyclin D1 degradation and the
effect was maximal at 5 ng/ ml (Figure 3E). Inhibition of
GSK3β did not result in changes in the level of cyclin D1
mRNA (Figure 3D). We noted that mutation of Thr286 to
alanine (Figure 2B), "knockdown" of GSK3 by siRNA or
nuclear export with leptomycin B (Figures 3A and 3E), all
failed to induce significant cyclin D1 accumulation.
Nonetheless, the ability of SB216763 and leptomycin B to
partially inhibit TSA-induced cyclin D1 degradation dem-Molecular Cancer 2006, 5:8 http://www.molecular-cancer.com/content/5/1/8
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Effect of GSK3β and CRM1 inhibition on TSA induced cyclin D1 degradation Figure 3
Effect of GSK3β and CRM1 inhibition on TSA induced cyclin D1 degradation. A, MCF-7 cells were transfected with or without 
GSK3β specific siRNA pools. 72 h after transfection, cells were treated with TSA (1 µM) alone or in the presence of MG132 
(50 µM) for 6 h. Cell lysates were separated by 4–20 % SDS-PAGE and immunoblot analysis was done using antibodies against 
GSK3 α/β, cyclin D1 and actin. B, Effect of TSA on GSK3β levels and activity. MCF-7 cells were cultured in the absence or 
presence of TSA for 6 h. Immunoblot analysis was done with antibodies against GSK3, cyclin D1 and actin. C, partial inhibition 
of TSA induced cyclin D1 degradation by the GSK3 inhibitor SB216763. Cells were cultured for 24 h with the indicated con-
centrations (µM) of SB216763 and then treated for 6 h with TSA (1 µM). Immunoblot analysis was done with antibodies against 
β-Catenin, cyclin D1 and actin. D, Effect of SB216763 on GSK3β mRNA expression. MCF-7 cells were cultured for 24 h in the 
absence or presence of SB216763 (10 µM) and treated with TSA (1 µM) 12 h. Semi-quantitative RT-PCR analysis was done 
with primers for GSK3β, cyclin D1 and CGI-128 as a loading control. E, effect of the CRM1-dependent nuclear export inhibitor 
Leptomycin B (LMB) on TSA induced cyclin D1 degradation. MCF-7 cells were pretreated for 1 h with the indicated concentra-
tions (ng/mL) of LMB and then treated with TSA (1 µM) for 6 h. Alternatively MCF-7 cells were cultured in the presence of the 
indicated concentrations (ng/mL) of LMB for 6 h. Immunoblot analysis was done with antibodies against cyclin D1 and actin.
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onstrates the active involvement of GSK3β-mediated
nuclear export. These observations suggest that GSK3β-
mediated nuclear export enhances the rate of TSA-induced
cyclin D1 degradation in MCF-7 cells. The GSK3β-inde-
pendent degradation of cyclin D1 has been described pre-
viously [8]. In addition, we have demonstrated that the
inhibition of 26S proteasomal degradation by MG132
results in the accumulation of both wild type and Thr286
mutant GFP-Cyclin D1 in MCF-7 cells (Figure 2B). It is
thus possible that TSA can induce cyclin D1 degradation
independently of GSK3β in this cell line.
Inhibition of TSA induced cyclin D1 degradation
The lack of specificity inherent to many inhibitors has pre-
viously led to proteins being linked mistakenly to one
degradation pathway or another. Indeed, the peptide
aldehydes ALLN and MG132 have been shown to inhibit
cysteine and serine proteases such as calpains and cathep-
sins [24]. We thus investigated the possibility that the sta-
bilization of cyclin D1 in MCF-7 cells by MG132 did not
result from the inhibition of 26S proteasome activity
alone. Lactacystin, a more specific inhibitor of the 26S
proteasome than MG132 [25,26], was used to investigate
the possibility that cyclin D1 degradation occurs in the
absence of 26S proteasome activity. Lactacystin partially
abolished TSA-induced cyclin D1 degradation (Figure
4A). The partial inhibition of TSA-induced cyclin D1 deg-
radation by lactacystin was observable at concentrations
as low as 0.5 µM and did not increase even at concentra-
tions as high as 10 µM (Figures 4A,B and 4C). In contrast,
inhibition of calpain 1 and calpain 2 by ALLM (Figure 3C)
or the inhibition of lysosomal degradation with NH4Cl
(Figure 4B) or cathepsin inhibitor-1 (CATI-1) (not
shown) had no effect on TSA induced loss of cyclin D1
protein expression in MCF-7 cells. It remains unclear why
lactacystin is less effective than MG132 at inhibiting TSA-
induced cyclin D1 degradation. This differential effect on
stability was also observed when cyclin D1 was ablated by
treatment with cycloheximide. Similarly, the peptide alde-
hyde inhibitors ALLN and MG132 but not lactacystin or
NLVS (a peptide vinyl sulfone proteasome inhibitor)
inhibited cycloheximide-induced cyclin D1 ablation in
MCF-7 cells (see Additional file 1). Interestingly, treat-
ment of asynchronous populations of MCF-7 cells with 10
µM lactacystin or 100 µM ALLM for 6 h resulted in
decreased cyclin D1 levels (Fig. 4D). Co-treatment with
MG132 inhibited lactacystin- or ALLM-induced cyclin D1
loss (Fig. 4D). The inhibition of TSA-induced cyclin D1
degradation by both MG132 and lactacystin confirms our
previous observation, that the 26S proteasome plays an
important role in TSA-induced cyclin D1 degradation.
Discussion
In our previous work we found that TSA-induced cyclin
D1 degradation is accompanied by Skp2 up-regulation
and this activity can be abolished by Skp2 siRNA [15]. The
rapid degradation of cyclin D1 has been linked to its
phosphorylation on Thr286 by GSK3β. The rapid decline
of cyclin D1 during S phase is required for cell cycle pro-
gression and has been linked to CRM1-dependent nuclear
export and ubiquitin-dependent degradation of the cyclin
within the cytoplasm. CRM1-dependent nuclear export of
cyclin D1 requires prior phosphorylation of residue
Thr286 by GSK3β. It has therefore been proposed that
GSK3β migrates into the nucleus at S phase where the
kinase phosphorylates cyclin D1 leading to its rapid
nuclear export and degradation within the cytoplasm.
Although initial studies suggested that cyclin D1 ubiquit-
ylation requires prior phosphorylation by GSK3β, cyclin
D1 ubiquitylation can occur independently of this kinase
[8,10]. Consistent with this observation, cyclin D1 levels
never rise significantly above that of normal cells even
when greatly overexpressed at the mRNA level [2]. In
addition, cyclin D1b, a splice variant lacking the C-termi-
nal sequence including Thr286, does not always exhibit
enhanced protein stability [9]. Interestingly, antizyme-
induced cyclin D1 degradation occurs in spermidine
treated cells via the 26S proteasome but does not require
the prior polyubiquitylation of the cyclin [27]. It should
be noted however, that spermidine induced cyclin D1
degradation occurs at a slower rate than that observed fol-
lowing DNA damage or TSA treatment. The precise mech-
anisms that govern the regulation of cyclin D1
degradation thus remain unclear.
Our present findings suggest that the rapid TSA-induced
degradation of cyclin D1 requires GSK3β activity. The
inhibition of GSK3β- or CRM1-dependent nuclear export
however, only partially inhibited the cyclin D1 degrada-
tion response to TSA. In contrast, MG132 completely
abolished this protein loss. The underlying reasons for
this differential effect are unclear but may due to GSK3β-
independent or nuclear degradation of cyclin D1 [8,9].
TSA-induced cyclin D1 degradation could also be inhib-
ited by other 26S proteasome inhibitors such as lactacys-
tin. In contrast, the inhibition of calpains or cathepsins
did not affect TSA-induced cyclin D1 degradation.
Cyclin D1 degradation clearly occurs via the ubiquitin-
dependent degradation pathway, and its degradation at S
phase must therefore be closely liked to the activity of the
E3 complexes that mediate its ubiquitylation. It is con-
ceivable, that the up-regulation of a particular E3 complex
or its activity and not an increase in GSK3β-mediated
nuclear export that is responsible for the decline of cyclin
D1 levels at S phase. Although the Skp2 E3 ligase has been
linked to cyclin D1 degradation, the exact nature of this
relationship remains unclear [13,28]. In proliferating
cells, Skp2 levels become elevated around the time cyclin
D1 levels decline at the G1/S-phase boundary and Skp2Molecular Cancer 2006, 5:8 http://www.molecular-cancer.com/content/5/1/8
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Effect of lactacystin on TSA induced cyclin D1 degradation Figure 4
Effect of lactacystin on TSA induced cyclin D1 degradation. A, MCF-7 cells were pretreated with lactacystin (10 µM) for 1 h 
and then treated with TSA (1 µM) for 6 h. Cell lysates were separated by 4–20 % SDS-PAGE and immunoblot analysis was 
done using antibodies against cyclin D1 and actin. B, effect of ammonium chloride and lactacystin on TSA induced cyclin D1 
degradation. MCF-7 cells were pretreated with the indicated concentrations of ammonium chloride (10 mM) and/or lactacystin 
(10 µM) for 1 h and then treated with TSA (1 µM) for 6 h. Immunoblot analysis was done with antibodies against cyclin D1 and 
actin. C, Effects of ALLM, lactacystin and LMB on TSA induced cyclin D1 degradation. MCF-7 cells were pretreated with ALLM 
(100 µM), lactacystin (10 µM) or LMB (10 ng/mL) for 1 h and then treated with TSA (1 µM) for 6 h. Immunoblot analysis was 
done with antibodies against cyclin D1 and actin. D, Lactacystin and ALLM induced cyclin D1 loss is inhibited by MG132. MCF-
7 cells were treated with lactacystin (10 µM) or ALLM (100 µM) with or without MG132 (50 µM) for 6 h. Immunoblot analysis 
was done with antibodies against cyclin D1 and actin.
DMolecular Cancer 2006, 5:8 http://www.molecular-cancer.com/content/5/1/8
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siRNA abolishes this decline. In addition, 26S proteas-
omes have been localized to both the cytoplasm and
nucleus of mammalian cells [29]. It is thus possible, that
simply increasing the rate of cyclin D1 ubiquitylation
would result in its increased degradation independent of
nuclear export. We have shown previously, that TSA-
induced cyclin D1 degradation in asynchronously grow-
ing MCF-7 cells is associated with a rise in Skp2 protein
levels [15]. It is also possible, that TSA induces the expres-
sion of other ubiquitin ligases involved in cyclin D1 deg-
radation. We propose that treatment with TSA results in
the increased ubiquitylation and degradation of cyclin D1
in MCF-7 cells. The rate of TSA induced cyclin D1 degra-
dation is further enhanced by the constitutive phosphor-
ylation of Thr286 by GSK3β, allowing for the subsequent
nuclear export and degradation of polyubiquitylated cyc-
lin D1 within the cytoplasm.
We noted that lactacystin was less effective than MG132 at
inhibiting TSA-induced cyclin D1 degradation. The use of
appropriate controls has thus been recommended when
employing peptide aldehydes as proteasome inhibitors in
cell culture studies [25]. Agents that inhibit calpains and
cysteine proteases but not proteasomes can be used to rule
out the involvement of these proteins. In addition, the
involvement of 26S proteasomes in mediating peptide
aldehyde sensitive degradation can be confirmed with
more specific proteasome inhibitors e.g. lactacystin and
epoxomicin [25]. The existence of additional protein deg-
radation pathways has been suggested previously based
on studies of protein degradation in rat skeletal muscle
[30]. ALLN but not lactacystin inhibited cyclin D1 loss
induced by serum starvation or treatment with agents
such as actinomycin D and lovastatin [31]. Moreover,
studies by Cotelle et al., [32] have provided compelling
evidence for the existence of an MG132 sensitive cytosolic
protease. Our findings clearly implicate the ubiquitin-
dependent degradation pathway in facilitating TSA-
induced cyclin D1 degradation. We cannot however dis-
tinctly rule out at present, the possibility that TSA-induced
cyclin D1 degradation can occur independently of GSK3β
or 26S proteasomes.
Cyclin D1 has been shown to play an important role in
breast cancer cell proliferation [19]. Furthermore, cyclin
D1 overexpression has been shown to confer resistance to
antioestrogens in breast cancer cells [33] and has been
identified as a negative predictive factor for tamoxifen
response [34]. Drug-induced cyclin D1 repression not
only inhibits breast cancer cell proliferation but also sen-
sitizes these cells to other agents such as CDK and Akt
inhibitors [16]. Cyclin D1 ablation thus presents an
important therapeutic strategy for the treatment of human
breast cancer. Thiazolidinediones and their derivatives
have recently been shown to induce proteasome mediated
proteolysis of cyclin D1 in MCF-7 cells [18]. In contrast to
TSA however, these compounds induce cyclin D1 degra-
dation independently of GSK3β. Our observation that
TSA induces cyclin D1 degradation suggests that HDAC
inhibitors may also have therapeutic potential as cyclin
D1 ablative agents. The identification of novel HDAC
inhibitors with potent in vivo activity that induce cyclin
D1 degradation is thus desirable and forms an active part
of our current research focus.
Conclusion
In the present study, we have investigated further, the
mechanisms whereby TSA induces cyclin D1 degradation
on MCF-7 cells. We have demonstrated that TSA enhances
cyclin D1 degradation at least in part through the ubiqui-
tin-26S degradation pathway. In addition we have also
identified GSK3β as an important mediator of TSA-
induced cyclin D1 degradation via this pathway. Drug-
induced cyclin D1 ablation protects against breast cancer
development, inhibits cancer cell proliferation and thus
presents an important therapeutic strategy for treating
and/ or preventing breast cancer. The findings presented
in this study suggest that HDAC inhibitors may have ther-
apeutic potential as cyclin D1 ablative agents for the treat-
ment of breast cancer.
Methods
Reagents
Carbobenzoxy-leucyl-leucyl-leucinal (Z-LLL-CHO,
MG132), N-acetyl-leucyl-leucyl-norleucinal (LLnL, ALLN,
MG101), lactacystin, Z-Phe-Gly-NHO-Bz (Z-FG-NHO-Bz,
Cathepsin inhibitor I, CATI-1), NIP-Leu3-vinyl sulphone
(NLVS) and N-acetyl-leucyl-leucyl-methional (ALLM, Cal-
pain Inhibitor II) (Calbiochem, VWR International Ltd.,
Lutterworth, United Kingdom) were dissolved in DMSO
at appropriate concentrations and aliquots stored at -
80°C. Stock solutions of TSA in ethanol, aqueous ammo-
nium chloride (NH4Cl) and leptomycin B in 70% (v/v)
methanol (Sigma-Aldrich; Dorset, United Kingdom) were
stored at -20°C. The GSK3-specific inhibitor SB216763
(Tocris Bioscience, Avonmouth, United Kingdom) was
dissolved in DMSO and stored at -20°C. Antibodies to
cyclin D1, actin, Sp1 and GFP (Santa Cruz Biotechnology,
Santa Cruz, CA), and β-Catenin (Transduction Laborato-
ries, BD Biosciences Ltd., Oxford, United Kingdom) were
used.
Cell cultures
MCF-7 cells (American Type Culture Collection, Rock-
ville, MD) were cultured in DMEM supplemented with
10% (v/v) fetal calf serum, 2 mM L-glutamine, 100 units/
ml penicillin and 100 µg/ml streptomycin at 37°C in
humidified 5% CO2.Molecular Cancer 2006, 5:8 http://www.molecular-cancer.com/content/5/1/8
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Site-directed mutagenesis
The pEGFP-cyclin D1 plasmid vector was mutated to cre-
ate pEGFP-cyclin D1T286A, pEGFP-cyclin D1T288A  and
pEGFP-cyclin D1T286A, T288A. Site-directed mutagenesis was
performed using a QuikChange® II kit (Stratagene) accord-
ing to the manufacturer's instructions. Mutation of T286A
was achieved using the primer pair forward, 5'-TGGACCT-
GGCTTGCGCACCCACCGA-3', and reverse, 5'-TCGGT-
GGGTGCGCAAGCCAGGTCCA-3', and T288A using
forward, 5'-TTGCACACCCGCCGACGTGCGGGAC-3',
and reverse, 5'-AACGTGTGGGCGGCTGCACGCCCTG-3'.
The T286A, T288A double mutant was generated by
mutating the GFP-Cyclin D1T286A plasmid construct with
the T288A primer pair.
Immunoblot analysis
Cells treated as indicated were harvested in 5 ml of
medium, pelleted by centrifugation (1,000 × g for 5 min
at 4°C), washed twice with ice-cold PBS and lysed in ice-
cold HEPES buffer [50 mM HEPES (pH 7.5), 10 mM
NaCl, 5 mM MgCl2, 1 mM EDTA, 10% (v/v) glycerol, 1%
(v/v) Triton X-100 and a cocktail of protease inhibitors]
on ice for 30 min. Lysates were clarified by centrifugation
(15,000 × g for 10 min at 4°C) and the supernatants then
either analyzed immediately or stored at -80°C. Equiva-
lent amounts of protein (20–50 µg) from total cell lysates
were resolved by SDS-PAGE using precast 4–12% Bis-Tris
gradient gels (Invitrogen Ltd., Paisley, United Kingdom)
and transferred onto polyvinylidene difluoride (PVDF)
membranes (Hybond P; Amersham Biosciences United
Kingdom Limited, Little Chalfont, United Kingdom) with
a Novex XCell system (Invitrogen). Membranes were
blocked overnight at 4°C in blocking buffer [5% (w/v)
nonfat dried milk, 150 mM NaCl, 10 mM Tris (pH 8.0)
and 0.05% (v/v) Tween 20]. Proteins were detected by
incubation with primary antibodies at appropriate dilu-
tions in blocking buffer overnight at 4°C. Blots were then
incubated at room temperature with horseradish peroxi-
dase-conjugated secondary antibody. Bands were visual-
ized by enhanced chemiluminescence (Supersignal West
Pico; Perbio Science UK Ltd., Cheshire, United Kingdom)
followed by exposure to autoradiography film (Kodak
BioMax ML-light or MR-1).
Semi-quantitative RT-PCR analysis
For RT-PCR analyses, cells were washed with PBS buffer
and lysed directly in the culture plate using RTL buffer
(Oiagen). RNA was extracted using an RNeasy Kit (Qia-
gen) followed by cDNA synthesis and a 25 cycle PCR reac-
tion using a One-Step RT-PCR kit (Qiagen). The annealing
temperatures of the primers for Cyclin D1 amplification
(Forward 5'-aacagaagtgcgaggaggag-3'; Reverse 5'-
ctggcattttggagaggaag-3') was 55°C. GSK3β (Forward 5'-
cagcaaggtgacaacagtgg-3'; Reverse 5'-ggaacatagtccagcac-
caga-3') and CGI-128 (Forward 5'-ggaattccagcggtggtggttc-
cgcg-3'; Reverse 5'-ccccccgggagctgggaccaggat-3')
amplification the annealing temperatures were 58°C and
68°C respectively. Optimization reactions were carried
out to ensure the reactions were within the exponential
amplification window. Reaction products were resolved
on 2 % agarose gels containing 10 µg/ml ethidium bro-
mide and visualized with a UV transilluminatior.
siRNA/ Plasmid transfection
MCF-7 cells were transfected with commercially available
siRNA oligonucleotide pools (Dharmacon, Perbio) using
Oligofectamine transfection reagent (Invitrogen) as previ-
ously described [15]. Fugene 6 transfection reagent
(Roche Diagnostics Ltd, East Sussex, United Kingdom)
was used for DNA plasmid transfection. Asynchronous
cell populations at a density of 50–60% in 6-well plates or
on coverslips were transfected with 1–2 µg of plasmid
DNA, following the formation of lipid-DNA complexes
for 20 min at room temperature in Optimem I medium
(Invitrogen). Complexes were added directly to cells
growing in 2 ml DMEM and incubated for 5 h followed by
washing with PBS buffer and addition of fresh DMEM.
Cells were normally used in experiments 24 h following
transfection and the recombinant proteins detected by
immunoblotting, or by fluorescent microscopy as previ-
ously described
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Additional File 1
Inhibition of TSA and cycloheximide-induced cyclin D1 ablation. A, 
MCF-7 cells were pretreated with lactacystin (0.5–5 µM) for 1 h and 
then treated with TSA (1 µM) for 6 h. Cell lysates were separated by 4–
20 % SDS-PAGE and immunoblot analysis was done using antibodies 
against cyclin D1 and actin. B, MCF-7 cells were pretreated with lacta-
cystin (0.5–5 µM, top panel) or MG132 (50 µM, bottom panel) for 1 h 
and then treated with cycloheximide (Chx) (5–50 µM) for 1 h. Cell 
lysates were analyzed as in A. C, MCF-7 cells were pretreated with lacta-
cystin (10 µM), NLVS (10 µM), ALLN (100 µM) or MG132 (50 µM) 
for 1 h and then treated with Cycloheximide (50 µM) for 2 h. Cell lysates 
were separated by 4–20 % SDS-PAGE and immunoblot analysis was done 
using antibodies against cyclin D1 and actin.
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